ArticleInfection and drug resistance2025
Analysis of Carbapenem-Resistant Enterobacterales Resistance in a Hospital in Kunming Over the Past Two Years.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct-from-Specimen Detection of Major Carbapenemases by Carbapenem-Resistant K.N.I.V.O. Detection K-Set: Comparative Analysis of Accuracy and Turnaround Time.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the species distribution, clinical prevalence, antimicrobial profiles, and carbapenemase phenotypes of carbapenem-resistant Enterobacterales (CRE) isolated from a tertiary hospital over the past two years, thereby providing a reference for clinical anti-infection strategies and hospital infection control measures. Methods: A retrospective analysis was performed to examine the distribution of CRE strains isolated from inpatients at a tertiary hospital between 2023 and 2024, their resistance profiles to commonly used antibiotics and carbapenemase phenotypes. Results: A total of 239 distinct CRE strains were identified between 2023 and 2024, predominantly in sputum, urine, and blood samples. The primary species of CRE include Conclusion: The CRE isolation and resistance rates in this hospital are similar to international trends, both showing an upward trend, and comparison with domestic data reveals significant regional differences. CRE infections are difficult to treat and have a high mortality rate. Therefore, to meet the needs of Infection Prevention and Control, it is necessary to strengthen the monitoring of CRE resistance in this institution, contributing to the prevention, control, and clinical management capabilities for infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.